Navigation Links
Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
Date:3/5/2009

66% of evaluable heavily-pretreated patients in the high dose groups achieved disease stabilization. ProLindac was well tolerated overall.

DALLAS, March 5 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), announced today positive safety and efficacy results from its Phase 2 monotherapy clinical study of ProLindac(TM) in late-stage, heavily pretreated ovarian cancer patients. In this monotherapy study 66% of patients who received the highest dose achieved clinically meaningful disease stabilization according to RECIST criteria. No patient in any dose group exhibited any signs of acute neurotoxicity, which is a major adverse side-effect of the approved DACH platinum, Eloxatin, and ProLindac was well tolerated overall. The maximum tolerated dose of ProLindac was established as well as the recommended dose levels for future combination studies.

"We are very pleased with these results. ProLindac was well tolerated in an absolute sense and relative to commercially-available platinum therapies. We saw significant DACH platinum activity and efficacy in patients at the highest dose levels which is very encouraging given that this study involved monotherapy in a heavily pretreated patient population that typically only respond to an aggressive drug combination," commented Dr. David Nowotnik, Access' Senior Vice President R&D. "The DACH platinum activity level seen benchmarked favorably with published studies of monotherapy oxaliplatin in similar but less heavily pre-treated patient populations. Having achieved the recommended dose for future combination studies, we look forward to moving ahead in the clinic ourselves and with our regional partners."

This 26 patient Phase 2 study explored 3 different dose levels and 2 dosing regimens of ProLindac as a monotherapy treatment for advanced ovarian cancer, to provide data on the monotherapy anticanceractivity and safety of ProLindac. Of pati
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
2. First U.S. Patients Enrolled in the REALISM Continued Access Study
3. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
4. Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries
5. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
6. Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures
7. St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins
8. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
9. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
10. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
11. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 2015 DURECT Corporation (Nasdaq: DRRX ... , President and CEO, will be presenting at ... 8 at 11:45 a.m. Eastern Time.  The conference ... in New York City.  Investors and analysts that ... meeting through the conference organizers at http://www.cantorconferences.com/health-registration/health-investors ...
(Date:6/29/2015)... -- According to a new market research report ... Mode of treatment (Surgical, Laparoscopic, Percutaneous), Application (Liver, Lung, Kidney, ... by MarketsandMarkets, the global Tumor Ablation Market Is Poised to ... 11.5% from 2015 to 2020. Browse 72 ... igures spread through 330 P ages ...
(Date:6/29/2015)... , June 29, 2015 The Parenteral Drug ... New Jersey Board of Professional Engineers and ... of courses to professional engineers for continuing professional competency ... demonstrates the value and quality of PDA,s professional education ... lecture courses and hands-on professional training at the Training ...
Breaking Medicine Technology:DURECT to Present at the Cantor Fitzgerald Healthcare Conference 2Tumor Ablation Market Worth $515.2 Million by 2020 2Tumor Ablation Market Worth $515.2 Million by 2020 3Tumor Ablation Market Worth $515.2 Million by 2020 4
(Date:6/30/2015)... NV (PRWEB) , ... June 30, 2015 , ... ... returned to the U.S. after a 5-day tour in India. During her ... currently collaborating with Trivedi Master Wellness™ and Transformational Leader/Internationally Beloved Spiritual ...
(Date:6/30/2015)... ... , ... Skin Brushing (also known as Body Brushing) is a wonderful daily practice all year ... is more exposed to the elements. , Dry Skin Brushing takes only 10 minutes per ... dead cells and toxins on skin's surface. Skin is the largest organ of elimination and ...
(Date:6/30/2015)... NJ (PRWEB) , ... June 30, 2015 , ... ... announced the general availability of three new apps – AvePoint Watermark, ... Online. With the addition of these apps, workers can better streamline everyday business operations ...
(Date:6/30/2015)... ... 30, 2015 , ... Some may define success as the sum of small ... York State Athletic Trainers’ Association (NYSATA) and its members continue to be acknowledged and ... and a number of members also received honors at the national level. ...
(Date:6/30/2015)... ... June 30, 2015 , ... Intellitec Solutions has announced ... update to Dynamics CRM. With the enhanced changes and new procedures involved with updating ... agenda will feature a look at the new user interface and what it will ...
Breaking Medicine News(10 mins):Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 2Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 3Health News:Back in Stock: Keep Skin and Lymphatic System Healthy with Dry Skin Brushes from Sublime Beauty® 2Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 2Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 3Health News:AvePoint Enhances Workforce Productivity and Document Protection on Microsoft Office 365 with the Release of Three New Apps 4Health News:NYSATA and Members Recognized with National Awards 2Health News:NYSATA and Members Recognized with National Awards 3Health News:Intellitec Solutions to Host Microsoft CRM 2015 Update Webinar 2
... (HealthDay News) -- An investigational drug called pridopidine seems ... progressive movement disorder Huntington,s disease, researchers report. Huntington,s ... The new drug stabilizes dopamine signaling in areas of ... to the study authors, this is the first drug ...
... TORONTO, Ont., Nov. 7, 2011St. Michael,s Hospital announced ... Grand Challenges Explorations, an initiative created by the ... worldwide to test unorthodox ideas that address persistent ... an infectious disease consultant, will pursue an innovative ...
... HealthDay Reporter , MONDAY, Nov. 7 (HealthDay News) -- ... one of the safest over-the-counter medications. It,s approved for use ... use during pregnancy. But an Ohio pediatrician thinks ... popularly known as Tylenol -- particularly in people with asthma. ...
... records have been going electronic, and patients, caregivers, ... new digital world of health information. Now three ... large populationpeople with disabilitiescan best access this information. ... the Inglis Foundation, also based in Philadelphia, are ...
... The Children,s Hospital of Philadelphia announced today that it ... created by the Bill & Melinda Gates Foundation that ... persistent health and development challenges. Terri ... and Professor of Pediatrics at the Perelman School of ...
... has been awarded to the Scott & White Healthcare Cancer ... investigational drugs for the prevention and treatment of cancer. It ... award from the Cancer Prevention Research Institute of Texas (CPRIT), ... research in the state. The CRI grant is ...
Cached Medicine News:Health News:New Drug Shows Promise Against Huntington's Disease 2Health News:New Drug Shows Promise Against Huntington's Disease 3Health News:St. Michael's Hospital receives Grand Challenges Explorations funding 2Health News:Experts Debate Tylenol's Safety for Asthmatic Kids 2Health News:Experts Debate Tylenol's Safety for Asthmatic Kids 3Health News:Grant will help bridge digital divide for people with disabilities 2Health News:Grant will help bridge digital divide for people with disabilities 3Health News:The Children's Hospital of Philadelphia receives Grand Challenges Explorations funding 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: